Nivolumab-Induced Membranoproliferative Glomerulonephritis with Nephrotic Syndrome (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0694; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Prior ICI exposure included ipilimumab complicated by thrombocytopenia and Sjögren-like syndrome, then T-VEC (a year later), followed by nivolumab monotherapy 4 months later...The patient was successfully tapered off prednisone...Importantly, rituximab may facilitate safe ICI rechallenge, with recent series reporting 75% success without relapse. Early recognition and appropriate treatment are critical to optimize both renal and oncologic outcomes."
Fibrosis • Glomerulonephritis • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lupus Nephritis • Melanoma • Nephrology • Renal Disease • Solid Tumor • Thrombocytopenia
|
|
Jonathan Mina; Ali Mehdi; Crystal A. Gadegbeku
|